Key Takeaways
- Execution-led quarter, US drags: Revenue grew 4.3% QoQ in constant currency, driven by strong UK and Middle-East execution, while the US disappointed on Oracle Cloud commerce softness and delayed decisions.
- Oracle business stabilizes: After prior-quarter softness, Oracle grew QoQ with positive deal momentum, though management sidestepped whether the lower run-rate is the new normal.
- Margins inch up, reinvestment stays: Operating EBITDA reached 17.7%, up 40 bps QoQ on operating levers and currency, with management comfortable in the high-teens range and room to improve reinvested into capabilities.
- Account mining starting to pay: The FY23 priority is showing results in pockets, reflected in growth of >$1M and >$3M accounts, though management admits it underestimated the time needed.
- What to watch next quarter: Whether US decision cycles unlock as foundational pieces convert to growth, the pace of sub-contractor-to-employee conversion as a margin lever, and any NHS spend opening that would provide upside to a conservative baseline.
Demand Environment
- UK and Middle-East delivered, US lagged: UK growth was led by secure government and Oracle work, with management calling it solid in-quarter execution rather than a blip. Middle-East positively surprised with revenue uptick on a reduced account base. The US disappointed, impacted by a significant drop in Oracle Cloud commerce and deals taking up to two months longer than anticipated.
- Decision cycles stretching upward: Many US investments now go to the CEO or board for approval, a trend management expects to persist for at least the next two to three quarters. No ramp-downs were seen in Q4, but the elongation itself is the headwind.
- UK government frameworks offer multi-year tail: Mastek has a seat at the table on very large frameworks across borders, biometrics, police, DWP, and 29-30 councils running Oracle. Management expects market share gains over the next one to two years, with cross-pollination into Microsoft, AWS, and Salesforce.
- NHS bottomed out, but no recovery yet: Uncertainty in organization and leadership changes persists. Mastek has seen a bottoming out in its position, but some won deals were not ramped up by the customer. A conservative baseline reset has been taken for FY24, with potential upside if spend opens.
Hiral Chandrana: "We still see uncertainty in terms of the organization and the changes that they have. But we have seen a bottoming out in terms of our position, in that account."
US Business: Disappointment & Reset
- Oracle Cloud commerce was the drag: The US decline was not broad-based but concentrated in a significant drop in Oracle Cloud e-commerce work, compounded by decision delays. Management has tweaked strategy toward deeper account mining and healthcare, updating the value proposition to combine modernization and cloud transformation with a cost optimization pitch.
- Healthcare as the US pivot: Tremendous potential is seen in FY24 from US and Middle-East healthcare, particularly with Oracle's acquisition of Cerner and Mastek's Salesforce capabilities in payer and payvider solutions. Banner Health is now a vetted case study in the market. A greater than $5 million healthcare deal is expected to close in the next few weeks.
- Larger deal sizes targeted: In FY24, the average US deal size should be much larger than FY23, with overall order intake expected to be much better. Deals larger than $1 crore are an aspiration, with healthcare as a specific focus area.
- US margins under investment pressure: Pressure on US margins is predominantly from continued investment in the geography for growth. Management expects margins to return to normal levels as growth comes back.
Hiral Chandrana: "Many of the investments are going right up to the CEO or even to the board, in terms of approval cycles. And so that, I think, is a trend that we will see at least for the next two to three quarters."
Oracle & Salesforce: The Growth Engines
- Combined 45-47% of business, both expected to outgrow: Oracle and Salesforce together constitute a reasonable portion of overall business. Both are expected to continue growing higher than the company average, with deal momentum and order book backlog giving confidence of growing faster than FY24.
- Oracle stabilized and growing: After softness in the previous quarter, Oracle business grew QoQ with positive momentum on deal wins and revenue. New implementations and managed services deals were won in Q4, though discretionary spend remains under scrutiny. Management did not directly address whether the lower run-rate versus a year ago is temporary or the new normal.
- Salesforce seasonally weak Q4, strong outlook: Q4 is typically seasonally weak for the MST business, but outlook, momentum, and pipeline remain strong. Good year-on-year growth is expected in FY24.
- Non-linear components entering deals: Two deals greater than $5 million, one in US manufacturing and one in Australian utilities, included non-linear platform components. Workforce Scheduler, another non-linear solution, is gaining traction in healthcare. These investments were part of a medium-to-longer-term strategy.
Hiral Chandrana: "No, we expect both Oracle and Salesforce, both which constitutes a reasonable portion, anywhere from 45% to 47% for overall business. We expect both those to continue to grow higher than our company average."
Margins & Cost Structure
- 40 bps QoQ improvement, high-teens range held: Operating EBITDA reached 17.7% for Q4, up 40 bps QoQ led by improved operating levers and currency, while continuing to invest in capabilities. Full-year EBITDA was 17.8%, which management considers a good range to operate around.
- Employee costs rose despite headcount decline: Four factors drove the increase: currency conversion impact, headcount decline happening late in the month so cost was already in the P&L, investment in digital niche talent, and an onshore-offshore mix shift as UK secured government work requires more onshore resources. Rates are better onshore, so margin is protected.
- Sub-contractor conversion is a margin lever: Some secured government work requires security-cleared resources unavailable in the employment market, so they are hired as sub-contractors first and gradually converted to employees. Management is not comfortable with the current sub-contractor percentage and sees it as a lever to improve gross margin and EBITDA. Other expenses are expected to convert into employee benefits over time.
- Utilization improving, fresher bet paying off: Utilization has shown good improvement with room for further gains. The company made a tough call mid-year to continue onboarding freshers when competitors stopped, which hit utilization in previous quarters. Many of those freshers are now moving into billable roles.
Arun Agarwal: "We believe that that's a good range to operate around, and we want to operate in that range. Definitely in the mid to long-term, we want to come back to the higher EBITDA profile as we start achieving our growth target."
Vertical & Geographic Mix
| Vertical / Geography | Trend | Commentary |
|---|---|---|
| UK Secure Government | ▲ Strong growth | Solid in-quarter execution, not a blip; work of national critical importance; diversifying into police, biometrics, DWP, councils. |
| Middle-East | ▲ Positive surprise | Reduced accounts but revenue uptick; good order book momentum; digital services gaining traction in ServiceNow, Microsoft, Snowflake. |
| US | ▼ Disappointing | Oracle Cloud commerce drop and decision delays; foundational pieces expected to convert to growth in FY24. |
| BFSI / Professional Services | ▬ Account-specific | Growth driven by one very large US-headquartered organization with a deal win and ramp-up; not broad-based across the industry. |
| UK Health (NHS) | ▼ Bottomed, uncertain | Conservative baseline reset for FY24; potential upside if NHS opens spend, but probability assumed very low. |
| US & ME Healthcare | ▲ High potential | Oracle-Cerner acquisition and Salesforce payer/payvider capabilities create FY24 opportunity; Banner Health as vetted case study. |
| UK Private Sector | ▲ Stabilized, upticking | Defended real estate, reached stabilization mid-year, then saw decent upticks; growth area for FY24 but not top-three priority. |
Balance Sheet & Cash Flow
- DSOs elevated, recovery underway: Cash from operations reduced this year, with DSOs rising to 93 days. An internal team has been created to address this, and DSOs have already been brought down from 98 days in the prior quarter. The endeavor is to operate free cash flow in the 75-80% range, with a return to that band expected next year.
- Debt servicing on track: The company carries a repayment plan with sufficient cash flows to service debt from the MST acquisition, which will discharge over the next three years. No further debt is planned unless for inorganic activity.
- Creditors decrease is business-as-usual: The INR 160 crore decrease in creditors is due to timely payments and timing of contracts, not a one-off event.
- Evosys payout nearly complete: Two tranches of the Evosys promoter payout have been completed, with one final tranche pending in October 2023.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY24 growth | Industry-leading or a few percentage points above industry year-on-year growth; benchmarks against Tier 1 and larger Indian IT (7-9% range) plus mid/small-cap peers | FY24 |
| Oracle & Salesforce growth | Both to grow higher than company average, faster than FY24 | FY24 |
| US deal sizes | Average deal size much larger than FY23; deals larger than $1 crore an aspiration; overall order intake much better | FY24 |
| Free cash flow recovery | Return to 75-80% of operating cash flow range | FY24 |
| US decision cycles | Longer approval cycles (CEO/board level) to persist | At least next 2-3 quarters |
| UK government market share | Gains expected from large framework participation | Next 1-2 years |
| NHS contribution | Conservative baseline assumed; probability of deal spend treated as very low | FY24 |
| EBITDA margin | Operate in high-teens range; mid-to-long-term return to higher EBITDA profile as growth targets achieved | Mid-to-long-term (no specific date) |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Operating revenue | ₹709 cr, +7.7% QoQ and +22% YoY in INR terms; +5.3% QoQ in constant currency |
| Full-year FY23 revenue growth | 18.5% in constant currency |
| Operating EBITDA margin | 17.7%, +40 bps QoQ |
| Full-year FY23 operating EBITDA margin | ~17.8% |
| PAT | ₹72.6 cr, +8.2% QoQ |
| 12-month order backlog | $280 million, +5.2% QoQ and +22% YoY; +17.2% YoY in constant currency |
| 12-month order backlog (INR) | ₹1,794 cr, committed over next 12 months |
| Gross cash | ₹270 cr vs ₹325 cr in December 2022 |
| Attrition (LTM) | 21%, a drop of 700 bps from a year ago |
| Clients added | 28 during the quarter |
| Oracle and Salesforce combined revenue share | 45% to 47% of overall business |
| MST acquisition performance | 118% of the acquisition plan delivered |
| DSO | 93 days, improved from 98 days in the prior quarter |
| Cash flow from operations (full year FY23) | ₹100 cr vs ₹270 cr in the prior year |